6-溴-2-苯基-1H-咪唑并[4,5-B]吡啶 | 65147-89-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 6-溴-2-苯基-1H-咪唑并[4,5-B]吡啶
• 英文名称: 6-bromo-2-phenyl-3H-imidazo[4,5-b]pyridine
• 英文别名: 6-bromo-2-phenyl-1H-imidazo[4,5-b]pyridine
• CAS: 65147-89-9
• 化学式: C₁₂H₈BrN₃
• mdl: MFCD06685723
• 分子量: 274.12
• InChiKey: UQEYLXNLWAHTFF-UHFFFAOYSA-N

物化性质

• 熔点：
  >310 °C
• 沸点：
  333.8±52.0 °C(Predicted)
• 密度：
  1?+-.0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromo-2-phenyl-1h-imidazo[4,5-b]pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-2-phenyl-1h-imidazo[4,5-b]pyridine
CAS number: 65147-89-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H8BrN3
Molecular weight: 274.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴-2-苯基-1H-咪唑并[4,5-B]吡啶 在 盐酸 、 四(三苯基膦)钯 、 tin(II) chloride dihdyrate 、 potassium carbonate 作用下， 以 甲醇 、 乙醇 、 甲苯 为溶剂， 反应 26.5h， 生成 4-(2-phenyl-3H-imidazo[4,5-b]pyridin-6-yl)aniline hydrochloride
  参考文献：
  名称：

  Suzuki交叉偶联制备2,6-二取代咪唑并[4,5-b]吡啶的合成及其抗增殖活性。

  摘要：

  采用优化的 Suzuki 交叉偶联设计并合成了一系列新型 2,6-二苯基取代的咪唑并[4,5-b]吡啶，以评价其体外生物活性。使用模型反应评估和优化铃木偶联的条件。为了研究取代基对生物活性的影响，我们制备了杂环支架上6位苯环对位具有不同取代基的N-未取代和N-甲基取代的咪唑并[4,5-b]吡啶。 。在不同的人类癌细胞系上测定了抗增殖活性，并在正常外周血单核细胞（PBMC）上测定了具有潜在抗增殖活性的化合物的选择性。对羟基取代的衍生物 13 和 19 观察到显着的抗增殖活性，两者均对大多数测试的细胞系表现出强活性（IC50 1.45-4.25 μM）。未取代的N-甲基衍生物19被证明是最活跃的衍生物。接触化合物 19 后，几种癌细胞系中 G2/M 期停滞细胞出现剂量依赖性积累，这表明存在细胞周期阶段特异性的作用机制。此外，还评估了该系列新型衍生物对多种病毒的抗病毒活性，但大多数测试化合物并未表现出抗病毒活性。

  DOI：

  10.3390/molecules28207208
• 作为产物：
  描述：

  2-氨基-3,5-二溴吡啶 在 copper(l) iodide 、 三氯化铝 、 sodium hydride 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.67h， 生成 6-溴-2-苯基-1H-咪唑并[4,5-B]吡啶
  参考文献：
  名称：

  由无环am和胍合成嘌呤和其他稠合的咪唑。

  摘要：

  [反应：见正文]嘌呤，黄嘌呤和其他稠合的咪唑可以由am或胍制备，并在环融合时逆合成断开。闭环使用Cu（I）进行，不需要特殊的配体。该方法允许容易地修饰杂环核并且耐受环系统的功能性侧基。

  DOI：

  10.1021/ol0504751

文献信息

• Synthesis of Fused Imidazoles and Benzothiazoles from (Hetero)Aromatic <i>ortho</i>-Diamines or <i>ortho</i>-Aminothiophenol and Aldehydes Promoted by Chlorotrimethylsilane
  作者：Dmitriy Volochnyuk、Sergey Ryabukhin、Andrey Plaskon、Andrey Tolmachev

  DOI：10.1055/s-2006-950289

  日期：2006.11

  New convenient conditions for benzimidazole and benzothiazole syntheses are described. A set of benzimidazoles, 3H-imidazo[4,5-b]pyridines, purines, xanthines and benzothiazoles was readily prepared from (hetero)aromatic ortho-diamines or ortho-aminothiophenol and aldehydes using chlorotrimethylsilane in DMF as a promoter and water-acceptor agent, followed by oxidation with air oxygen.

  描述了苯并咪唑和苯并噻唑合成的新便利条件。一组苯并咪唑、3H-咪唑并[4,5-b]吡啶、嘌呤、黄嘌呤和苯并噻唑很容易由（杂）芳族邻二胺或邻氨基苯硫酚和醛在 DMF 中使用三甲基氯硅烷作为促进剂和水受体制备剂，然后用空气氧氧化。
• PI3K抑制剂及其制备方法与在制药中的应用
  申请人：复旦大学

  公开号：CN106117181A

  公开（公告）日：2016-11-16

  本发明属于医药技术领域，具体为PI3K抑制剂及其制备方法与在制药中的应用。本发明提供的PI3K抑制剂为如通式Ⅰ所示结构的化合物，或其药物上可接受的盐。经PI3K生物化学活性测试法测试，该化合物对PI3Kα和PI3Kγ具有良好的抑制活性，其中有多个化合物对PI3Kα和PI3Kγ的IC50值达到了纳摩尔级（＜100nM）。结果表明，这些化合物能够为受PI3K作用的增值性疾病的治疗提供有效性和选择性更好的抑制剂，进而有望开发出治疗第I型糖尿病、肺病、乳癌、前列腺癌、实体瘤、淋巴瘤、心血管疾病、类风湿性关节炎、白血病等的靶向药物。
• Bicyclic derivative, its production and use
  申请人：Oda Tsuneo

  公开号：US20050101647A1

  公开（公告）日：2005-05-12

  The present invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by formula: (wherein, R 1b is a C 6-10 aryl group which has substituent(s), and the like; T a is a single bond, a C 1-6 alkyl group, —CH 2 O—, and the like; X and Y are the same or different, and each is a nitrogen atom which may have substituent(s), and the like; the broken line is a single bond or a double bond; Z a is a nitrogen atom or CH; W is a single bond, an oxygen atom, and the like; Q is a C 6-10 aryl group which may have substituent(s) or an aromatic heterocyclic group which may have substituent(s)); or a salt thereof and a pharmaceutical composition comprising thereof.

  本发明提供了一种具有强效酪氨酸激酶抑制活性的杂环化合物，其化学式表示为：（其中，R1是具有取代基的C6-10芳基基团等；Ta是单键，C1-6烷基基团，—CH2O—等；X和Y相同或不同，每个都是氮原子，可以具有取代基等；断裂线是单键或双键；Z是氮原子或CH；W是单键，氧原子等；Q是具有取代基的C6-10芳基基团或具有取代基的芳香杂环基团）或其盐以及含有该化合物的药物组合物。
• 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses
  申请人：Kenda Benoît

  公开号：US20090312333A1

  公开（公告）日：2009-12-17

  The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

  本发明涉及2-氧代-1-吡咯烷衍生物，其制备过程，包含它们的药物组合物以及它们作为药物的用途。
• 2-OXO-1-PYRROLIDINE DERIVATIVES
  申请人：Kenda Benoit

  公开号：US20090156607A1

  公开（公告）日：2009-06-18

  The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

  本发明涉及2-氧代-1-吡咯烷衍生物、其制备过程、含有它们的药物组合物及其作为药物的用途。